What Axio Biosolutions does

Axio Biosolutions Private Limited is a Gujarat, India-headquartered medical device company founded in 2008 that develops and manufactures advanced hemostatic dressings and wound care products based on proprietary 100% chitosan biomaterial technology. Its core platform comprises two proprietary technologies — PBT® (Protonated Bioadhesive Technology) powering the Axiostat line for rapid bleeding control (Gauze, Patch, Military variants), and BMG® (Bioactive Microfiber Gelling Technology) powering the MaxioCel line for advanced wound care (Dressing, Surgical Site Dressing, Wound Gel, Irrigation Solution). Both product families are FDA 510(k)-cleared and CE-certified, with demonstrated performance metrics including 2-3 minute hemostasis, 25-30x absorption capacity, and 100% preclinical survival rates.

The company sells exclusively through a B2B channel model — a 200+ distributor network spanning 50+ countries across six continents, plus direct supply to government/military customers including the Indian Armed Forces (400K units deployed across 300+ battalions) and hospital systems. End customers span emergency/trauma care, military/defense, vascular/cath lab, and chronic/acute wound care segments. Pricing is quote-based and not publicly disclosed; revenue is generated through one-time product purchases by hospitals, military procurement, emergency services, and wound care patients. Manufacturing occurs at a 25,000 sqft GMP Class 10000, ISO 13485-certified facility in Ahmedabad with 2.5M unit annual capacity expandable to 7M units.

Axio has raised $20M+ in cumulative venture funding (Series A/B/B1) from Accel, Chiratae Ventures, Omidyar Network India, RNT Capital, TrueScale Capital, UC-RNT Fund, and GVFL. Recent strategic activity has focused on US market entry (Axiostat Patch, Ax-Surgi FDA 510(k)), LATAM expansion via MedSupply Brasil, and MaxioCel portfolio extension into surgical site and irrigation indications. The company holds 22+ patents and references 50+ clinical publications supporting its evidence-based positioning against established hemostatic competitors.

Name

Axio Biosolutions

Legal name

Axio Biosolutions Private Limited

Website

https://axiobio.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

101–250 employees

Short description

Axio Biosolutions is an India-based medical device company that manufactures FDA-cleared chitosan-based hemostatic dressings (Axiostat) and advanced wound care products (MaxioCel), sold through 200+ distributors across 50+ countries to military, hospital, emergency, and chronic wound care customers.

Ownership category

akta.pro rank

Product category

Hemostatic and Wound Care Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation) (HLAHALAC)

Keywords

• Hemostatic dressings
• Advanced wound care
• Chitosan biomaterials
• Bleeding control products
• Surgical wound dressings

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Product Sales: Sale of chitosan-based hemostatic dressings (Axiostat) and wound care products (MaxioCel). Products are sold through distribution partners globally and directly to healthcare facilities. Revenue is generated from one-time product purchases by hospitals, military, emergency services, and wound care patients.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Axio Biosolutions manufactures and sells chitosan-based hemostatic and advanced wound care medical devices under two product lines. The Axiostat line (Gauze, Patch, Military) provides rapid bleeding control within 2-3 minutes for trauma, emergency, military, and vascular closure applications using PBT technology. The MaxioCel line (Advanced Wound Dressing, Surgical Site Dressing, Wound Gel, Irrigation Solution) addresses chronic and acute wound management using BMG technology for exudate management and faster healing.

Product overview

Axio Biosolutions is a medical device company offering two main product lines built on proprietary chitosan technology. The Axiostat line (Gauze, Patch, Military versions) provides rapid bleeding control solutions for trauma, emergency, military, and vascular closure applications, powered by PBT® technology. The MaxioCel line (Advanced Wound Dressing, Surgical Site Dressing, Wound Gel, Irrigation Solution) provides advanced wound care solutions for chronic and acute wounds, powered by BMG® technology. Both product families are FDA 510(k)-cleared and CE-certified, with manufacturing facilities in Ahmedabad, Gujarat, India.

Differentiator

Problem solved

Functional benefit

Brands

• Axiostat: US FDA 510(k)-cleared and CE-certified hemostatic dressing made from 100% chitosan. Uses PBT (Protonated Bioadhesive Technology) for rapid bleeding control in emergencies, trauma, EMS, military, and vascular closures.
• MaxioCel

Products and services

• Axiostat Gauze US FDA 510(k)-cleared and CE-certified hemostatic dressing made from 100% chitosan using PBT (Protonated Bioadhesive Technology) to control moderate to severe bleeding within 2-3 minutes. Trusted in trauma, EMS, military, and vascular closure applications.
• Axiostat Patch FDA 510(k)-cleared hemostatic patch designed for rapid and effective hemostasis in radial and femoral vascular access closures. Features highly positive charge (Zeta potential ~36 mV) providing instant bioadhesion for PCI, electrophysiology, and cath lab procedures.
• Axiostat Military Battlefield-proven hemostatic gauzes and patches for control of massive bleeding in military operations. NSN codified for military procurement. Lightweight and portable with rugged camouflage vacuum-sealed packaging for field conditions.
• MaxioCel Advanced Wound Dressing

Quantifiable outcome

• Hemostasis time: 2-3 minutes (vs 6-13 minutes for competitors)
• +5 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• MedSupply Brasil LtdacoreChannel Partner/ Reseller/ DistributorDistributor partner in Latin America since 2021. Axio's wound care solutions filled a critical gap in their product portfolio. Described as most successful product launch in 15 years for the distributor.
• MediCorp Distribution Pte LtdcoreChannel Partner/ Reseller/ DistributorDistributor partner in Southeast Asia since 2020. Managing Director Dr. Lisa Chen describes partnership model as exceptional with exclusive territory rights and marketing support keeping them ahead of competitors.
• Highland Medical DistributorscoreChannel Partner/ Reseller/ DistributorDistributor partner in Europe since 2019. CEO James McKenzie states partnership transformed their business with bleeding control portfolio becoming top revenue generator within 6 months.
• Indian Armed ForcescoreChannel Partner/ Reseller/ DistributorMilitary customer using Axiostat (known as 'Bharat Ka Bandage') for battlefield bleeding control. 400K units deployed, 300+ battalions relying on products. NSN codified for military procurement.

Scale indicators15 records

Recent moves10 records

Expansion highlights6 records

Others

• Baxter International: Through its surgical solutions portfolio (e.g., Floseal hemostatic matrix), Baxter participates in surgical hemostasis, an adjacent category to Axiostat's hemostatic dressings. Indirect competitor in OR settings.

Broad incumbents

• Integra LifeSciences: Specialty medical device company with tissue technologies and wound management (Integra Dermal Regeneration Template, MediHoney). Competes in advanced wound healing alongside MaxioCel.
• ConvaTec: Established wound care and ostomy device maker (AQUACEL, DuoDERM) competing in advanced wound dressings, including chronic wound segments where MaxioCel targets diabetic foot ulcers, venous ulcers, and pressure ulcers.
• 3M Health Care (Solventum / KCI): Large diversified medical products player with a deep wound care and surgical portfolio following the Solventum / KCI spin-out (V.A.C. therapy, Tegaderm). Provides broad competitive overlap across wound dressings and acute care channels.
• Mölnlycke Health Care: Major wound care and surgical solutions company (Mepilex, Mepitel, Avance) with global hospital reach. Overlaps with MaxioCel in chronic and acute wound dressing categories.
• Smith+Nephew: Global medical device incumbent with a sizeable Advanced Wound Management portfolio (PICO, ALLEVYN, RENASYS). Competes broadly with MaxioCel in hospital and post-acute wound care settings.

Direct peers

• Medtrade Products (Celox): UK-based Medtrade manufactures the Celox range of chitosan hemostatic gauzes and granules, one of the closest direct substitutes to Axiostat in trauma, military, and EMS channels globally.
• Tricol Biomedical (HemCon): Tricol acquired HemCon and produces chitosan-based hemostatic dressings (HemCon Bandage) for military and trauma use, plus an advanced wound care portfolio that overlaps with Axiostat and MaxioCel.
• Marine Polymer Technologies: Develops and commercializes chitosan-based hemostatic and anti-infective medical products (e.g., m chitosan technology), competing in the same biomaterial wound-care and bleeding-control space as Axio.
• Teleflex (Z-Medica / QuikClot): Teleflex acquired Z-Medica and markets QuikClot Combat Gauze, the leading chitosan-based and kaolin-based hemostatic dressings used by US/allied militaries and EMS. Directly competes with Axiostat in trauma and military hemostasis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/axiobio
• LinkedInlinkedin.com/company/axio-biosolutions-private-limited

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds7 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Axio Biosolutions